Amicus Eyes Breakthrough Drug, PRV Revenue In Scioderm Buy
This article was originally published in Scrip
Amicus Therapeutics chairman and CEO John Crowley had special insight into the value of Scioderm's topical drug candidate Zorblisa (SD-101) – he's been a member of the small, private company's board of directors for two years and became convinced that Amicus could add value to the "breakthrough" treatment for epidermolysis bullosa (EB).
You may also be interested in...
CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.
Amryt Pharma: EIB Funds Secure Phase III For Rare Skin Disease Candidate And Cholesterol Drug License
Not many 18-month old rare and orphan disease-focused biotech companies have an approved product in their portfolio. Even fewer have persuaded the European Investment Bank to make a direct investment into their business. Amryt Pharma can claim both.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.